explore -WSS

explore

author：knowledge 2025-09-02 11:39:05 - browse：4

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Helping hospitals and community health centers plan for resilience

explore

focus

WSS

With measles on the rise, a personal story of a devastating disease

NVIDIA and Google execs on the future of AI and drug discovery

Iowa House, Senate pass 6

Petition to FDA: Get the lead out of consumer hair dyes

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Bulgari apologizes to China for listing Taiwan as a country after online backlash

hotspot

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

Why ADHD is under

New air purifier tech could be key to improving indoor air quality

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Medicare details structure of new drug price negotiation program

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Hepatitis C has a cure — but many Americans still lack access to it

N.Y. state detects polio case, first in the U.S. since 2013

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

knowledge

What to know about OceanGate, the company behind the missing Titanic submersible

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Study: Pain burden is higher in Black NFL players than white ones

Criminal prosecution for violating HIPAA: an emerging threat

NVIDIA and Google execs on the future of AI and drug discovery

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

entertainment

explore

focus

entertainment